Reducción de los niveles de IL16, IL7 y VEGF-A en SFC/EM
Publicado: 30 Nov 2015, 21:20
Un estudio interesante, de 100 pacientes y 79 controles sanos sobre 34 citoquinas, quimiocinas y factores de crecimiento en plasma se apunta como otro estudio de biomarcadores interesante. Los niveles de IL-16, IL-7, y VEGF-A aparecen como gravemente reducidos en enfermos de SFC/EM. Consideran que "este perfil es específico en los enfermos de SFC/EM, ya que el mismo análisis en infecciones crónicas y en enfermedades autoinmunes hepáticas, en que la fatiga persistente es un síntoma preeminente, no muestran los mismos cambios".
Me parece entender que tienen intención de realizar otros estudios con enfermos de EM / SFC y otras enfermedades con síntomas similares en el futuro ("Further studies of other
ME/CFS and overlapping disease cohorts are warranted in future").
[t]Reductions in circulating levels of IL-16, IL-7 and VEGF-A in myalgic encephalomyelitis/ chronic fatigue syndrome[/t].
Landi A, Broadhurst D, Vernon SD, Tyrrell DL, Houghton M.
Abstract
Recently, differences in the levels of various chemokines and cytokines were reported in patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) as compared with controls. Moreover, the analyte profile differed between chronic ME/CFS patients of long duration versus patients with disease of less than 3years. In the current study, we measured the plasma levels of 34 cytokines, chemokines and growth factors in 100 chronic ME/CFS patients of long duration and in 79 gender and age-matched controls. We observed highly significant reductions in the concentration of circulating interleukin (IL)-16, IL-7, and Vascular Endothelial Growth Factor A (VEGF-A) in ME/CFS patients. All three biomarkers were significantly correlated in a multivariate cluster analysis. In addition, we identified significant reductions in the concentrations of fractalkine (CX3CL1) and monokine-induced-by-IFN-γ (MIG; CXCL9) along with increases in the concentrations of eotaxin 2 (CCL24) in ME/CFS patients. Our data recapitulates previous data from another USA ME/CFS cohort in which circulating levels of IL-7 were reduced. Also, a reduced level of VEGF-A was reported previously in sera of patients with Gulf War Illness as well as in cerebral spinal fluid samples from a different cohort of USA ME/CFS patients. To our knowledge, we are the first to test for levels of IL-16 in ME/CFS patients. In combination with previous data, our work suggests that the clustered reduction of IL-7, IL-16 and VEGF-A may have physiological relevance to ME/CFS disease. This profile is ME/CFS-specific since measurement of the same analytes present in chronic infectious and autoimmune liver diseases, where persistent fatigue is also a major symptom, failed to demonstrate the same changes. Further studies of other ME/CFS and overlapping disease cohorts are warranted in future.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Enlace: http://www.ncbi.nlm.nih.gov/pubmed/26615570" onclick="window.open(this.href);return false;
Me parece entender que tienen intención de realizar otros estudios con enfermos de EM / SFC y otras enfermedades con síntomas similares en el futuro ("Further studies of other
ME/CFS and overlapping disease cohorts are warranted in future").
[t]Reductions in circulating levels of IL-16, IL-7 and VEGF-A in myalgic encephalomyelitis/ chronic fatigue syndrome[/t].
Landi A, Broadhurst D, Vernon SD, Tyrrell DL, Houghton M.
Abstract
Recently, differences in the levels of various chemokines and cytokines were reported in patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) as compared with controls. Moreover, the analyte profile differed between chronic ME/CFS patients of long duration versus patients with disease of less than 3years. In the current study, we measured the plasma levels of 34 cytokines, chemokines and growth factors in 100 chronic ME/CFS patients of long duration and in 79 gender and age-matched controls. We observed highly significant reductions in the concentration of circulating interleukin (IL)-16, IL-7, and Vascular Endothelial Growth Factor A (VEGF-A) in ME/CFS patients. All three biomarkers were significantly correlated in a multivariate cluster analysis. In addition, we identified significant reductions in the concentrations of fractalkine (CX3CL1) and monokine-induced-by-IFN-γ (MIG; CXCL9) along with increases in the concentrations of eotaxin 2 (CCL24) in ME/CFS patients. Our data recapitulates previous data from another USA ME/CFS cohort in which circulating levels of IL-7 were reduced. Also, a reduced level of VEGF-A was reported previously in sera of patients with Gulf War Illness as well as in cerebral spinal fluid samples from a different cohort of USA ME/CFS patients. To our knowledge, we are the first to test for levels of IL-16 in ME/CFS patients. In combination with previous data, our work suggests that the clustered reduction of IL-7, IL-16 and VEGF-A may have physiological relevance to ME/CFS disease. This profile is ME/CFS-specific since measurement of the same analytes present in chronic infectious and autoimmune liver diseases, where persistent fatigue is also a major symptom, failed to demonstrate the same changes. Further studies of other ME/CFS and overlapping disease cohorts are warranted in future.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Enlace: http://www.ncbi.nlm.nih.gov/pubmed/26615570" onclick="window.open(this.href);return false;